Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX

2024-04-02
专利侵权
NEW YORK, April 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of
Ventyx Biosciences, Inc. (NASDAQ: VTYX).
Shareholders who purchased shares of VTYX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/ventyx-biosciences-inc-loss-submission-form/?id=73654&from=4
CLASS PERIOD: October 21, 2021 to November 6, 2023
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) VTX958, the Company's lead clinical product candidate, was less effective in treating psoriasis than defendants had led investors to believe; (ii) as a result, VTX958's clinical and/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx's business prospects following the initial public offering were thus inflated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
DEADLINE: April 30, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/ventyx-biosciences-inc-loss-submission-form/?id=73654&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of VTYX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 30, 2024. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
SOURCE Gross Law Firm
更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。